Your session is about to expire
← Back to Search
Dose Escalation for Small Cell Lung Cancer
Study Summary
This trial is studying a drug called ZL-1310 in people with small cell lung cancer. The study will look at how safe and well-tolerated the drug is, as well as how
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the main goals and purposes of this clinical investigation?
"The primary objective of this clinical trial, lasting approximately 24 months, is to evaluate the incidence of dose-limiting toxicities. Secondary objectives include assessing the Objective Response Rate (ORR) per RECIST 1.1 criteria, Overall Survival (OS), and Pharmacokinetics (PK) specifically related to unconjugated payloads."
Has the FDA granted approval for dose escalation in medical treatments?
"Given that this is a Phase 1 trial, the safety rating for Dose Escalation would be relatively low at 1. Limited data is available to support both safety and efficacy at this stage of the study."
At present, how many distinct locations are simultaneously conducting this experimental investigation?
"A total of 10 clinical trial sites are currently recruiting patients, including Zai Lab Site 2013 situated in Detroit, Zai Lab Site 2018 located in Durham, and Zai Lab Site 2005 based in Duarte. Additionally, there are another ten locations where recruitment is taking place."
Is the enrollment for this medical study currently accepting new participants?
"According to the latest information available on clinicaltrials.gov, this particular clinical trial is not actively enrolling patients. The initial posting date was January 31st, 2024 and it was last updated on December 19th, 2023. However, there are currently a total of 278 other ongoing clinical trials that are actively seeking participants at this time."
Share this study with friends
Copy Link
Messenger